Mitochondria-Targeted Honokiol Confers a Striking Inhibitory Effect on Lung Cancer via Inhibiting Complex I Activity

Pan, Jing; Lee, Yongik; Cheng, Gang; Zielonka, Jacek; Zhang, Qi; Bajzikova, Martina; Xiong, Donghai; Tsaih, Shirng-Wern; Hardy, Micael; Flister, Michael; Olsen, Christopher M.; Wang, Yian; Vang, Ole; Neuzil, Jiri; Myers, Charles R.; Kalynaraman, Balaraman; You, Ming

Published in:
iScience

DOI:
10.1016/j.isci.2018.04.013

Publication date:
2018

Document Version
Publisher's PDF, also known as Version of record

Citation for published version (APA):
Pan, J., Lee, Y., Cheng, G., Zielonka, J., Zhang, Q., Bajzikova, M., Xiong, D., Tsaih, S-W., Hardy, M., Flister, M., Olsen, C. M., Wang, Y., Vang, O., Neuzil, J., Myers, C. R., Kalynaraman, B., & You, M. (2018). Mitochondria-Targeted Honokiol Confers a Striking Inhibitory Effect on Lung Cancer via Inhibiting Complex I Activity. iScience, 3, 192-207. https://doi.org/10.1016/j.isci.2018.04.013

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.

Take down policy
If you believe that this document breaches copyright please contact rucforsk@ruc.dk providing details, and we will remove access to the work immediately and investigate your claim.
Mitochondria-Targeted Honokiol Confers a Striking Inhibitory Effect on Lung Cancer via Inhibiting Complex I Activity

Jing Pan, Yongik Lee, Gang Cheng, ..., Charles R. Myers, Balaraman Kalyanaraman, Ming You
myou@mcw.edu

HIGHLIGHTS
Synthesis of mitochondria-targeted honokiol (Mito-HNK);
Mito-HNK inhibits mitochondrial complex I, and stimulates oxidizing peroxiredoxin-3
Mito-HNK suppresses the phosphorylation of mitoSTAT3
Mito-HNK has pronounced activity against lung cancer and its brain metastases

Pan et al., iScience 3, 192–207 May 25, 2018 © 2018 The Authors.
https://doi.org/10.1016/j.isci.2018.04.013
Mitochondria-Targeted Honokiol Confers a Striking Inhibitory Effect on Lung Cancer via Inhibiting Complex I Activity

Jing Pan, Yongik Lee, Gang Cheng, Jacek Zielonka, Qi Zhang, Martina Bajzikova, Donghai Xiong, Shirng-Wern Tsaih, Micael Hardy, Michael Flister, Christopher M. Olsen, Balaraman Kalyanaraman, and Ming You

SUMMARY

We synthesized a mitochondria-targeted honokiol (Mito-HNK) that facilitates its mitochondrial accumulation; this dramatically increases its potency and efficacy against highly metastatic lung cancer lines in vitro, and in orthotopic lung tumor xenografts and brain metastases in vivo. Mito-HNK is >100-fold more potent than HNK in inhibiting cell proliferation, inhibiting mitochondrial complex 1, stimulating reactive oxygen species generation, oxidizing mitochondrial peroxiredoxin-3, and suppressing the phosphorylation of mitoSTAT3. Within lung cancer brain metastases in mice, Mito-HNK induced the mediators of cell death and decreased the pathways that support invasion and proliferation. In contrast, in the non-malignant stroma, Mito-HNK suppressed pathways that support metastatic lesions, including those involved in inflammation and angiogenesis. Mito-HNK showed no toxicity and targets the metabolic vulnerabilities of primary and metastatic lung cancers. Its pronounced anti-invasive and anti-metastatic effects in the brain are particularly intriguing given the paucity of treatment options for such patients either alone or in combination with standard chemotherapeutics.

INTRODUCTION

Lung cancer is the leading cause of cancer deaths worldwide. At the time of diagnosis, metastatic dissemination is seen in many patients with either non-small-cell lung cancer (NSCLC) or small cell lung cancer (SCLC) (Planchard and Giroux Leprieur, 2011). The overall 5-year survival rate for lung cancer is still only 10%–15% (Planchard and Giroux Leprieur, 2011). The brain is the most common site for lung cancer metastasis; 25%–30% of patients with NSCLC and 80% of patients with SCLC will develop brain metastasis during the course of their disease. Because the blood-brain barrier (BBB) is impermeable to most chemotherapeutic drugs used for lung cancer, the only available therapies for brain metastases include whole-brain irradiation or surgical resection in eligible patients. Although some small-molecule tyrosine kinase inhibitors have shown efficacy in a subset of patients, the results have not been consistent owing to the relatively low cerebrospinal fluid (CSF)-to-plasma ratios (Goldberg et al., 2015). Therefore, discovering novel small molecule agents that can inhibit both primary and metastatic lung cancer, including brain metastases, is a critical unmet need.

Although many tumor cells rely on aerobic glycolysis as the major source of adenosine triphosphate (ATP) to fuel cell proliferation (the Warburg effect), increasing evidence indicates that mitochondria are indeed functional in most tumor cells (Cheng et al., 2012, 2013, 2014, 2015; Weinberg et al., 2010; Berridge et al., 2015). Recent profiling of cellular bioenergetics has provided new insights on the intermediacy of mitochondrial metabolism in tumor cells (Cheng et al., 2012, 2013, 2014, 2015; Weinberg et al., 2010; Berridge et al., 2015). Cancer cells without mitochondrial DNA (mtDNA), called rho0 or p0 cells, show delayed tumor formation (Tan et al., 2015). However, mtDNA can be acquired by transfer of whole mitochondria from the host animal, which normalizes mitochondrial respiration and restores tumorigenic potential (Dong et al., 2017). Furthermore, several anti-cancer agents were recently identified that specifically target mitochondrial function, such as resveratrol (Widlund et al., 2017) or metformin (Wheaton et al., 2014). Thus, targeting mitochondrial bioenergetics is emerging as a promising and viable therapeutic approach to inhibit the proliferation of both poorly glycolytic and highly glycolytic cancer cells (Cheng et al., 2012, 2013, 2014, 2015; Weinberg et al., 2010; Weinberg and Chandel, 2015). Honokiol (HNK), a key bioactive compound present in...
magnolia bark extracts, exhibits anti-cancer and anti-metastatic properties in a variety of in vitro and in vivo models (Pan et al., 2016; Arora et al., 2012). We previously demonstrated that high-dose HNK (37.5 μmol/kg) inhibits the development of squamous cell carcinoma (SCC) in a carcinogen-induced mouse model (Pan et al., 2014), in which HNK was shown to suppress mitochondrial respiration, decrease ATP levels, and increase the generation of reactive oxygen species (ROS) (Pan et al., 2014). Thus even though HNK is not specifically sequestered inside mitochondria, these findings revealed that HNK can directly target mitochondrial bioenergetics, leading to persistent inhibition of mitochondrial respiration in lung cancer cells (Pan et al., 2014). We therefore hypothesized that conjugating HNK to a compound that drives HNK into mitochondria should dramatically increase its antitumor efficacy and potency. There is ample evidence in the literature that supports the therapeutic efficacy of mitochondria-targeted triphenylphosphonium (TPP⁺)-linked agents in cellular and animal models and possibly in humans (Murphy and Smith, 2007; Gane et al., 2010; Tauskela, 2007; Snow et al., 2010; Murphy, 2016; Smith et al., 2012; Smith and Murphy, 2010). We therefore developed mitochondria-targeted honokiol (Mito-HNK) by attaching the bulky TPP⁺ group to HNK via a long alkyl chain, well separated from HNK’s aromatic structure. Published reports also indicate that increasing the lipophilicity of TPP⁺-conjugated compounds enhances their cellular and mitochondrial uptake (Smith et al., 2003; Asin-Cayuela et al., 2004; Ross et al., 2008; Finichiu et al., 2015). Lipophilic cations, including TPP⁺-based agents, selectively accumulate in cancer cells in vitro and in vivo owing to an elevated mitochondrial membrane potential (Summerhayes et al., 1982; Lampidis et al., 1985; Rideout et al., 1989; Modica-Napolitano and Aprille, 2001; Cheng et al., 2013). Another rationale for using Mito-HNK in this lung cancer brain metastasis study is the observation that the TPP⁺-based compound, [11C]-triphenylmethylphosphonium (TPMP), selectively accumulates in brain tumors (Madar et al., 1999).

Here we describe the synthesis and detailed in vitro and in vivo characterization of Mito-HNK. In human NSCLC lines derived from brain metastases and in an SCLC line with high metastatic potential, Mito-HNK proved to be more than 100-fold more potent than HNK in inhibiting cell proliferation, suppressing mitochondrial bioenergetics by inhibiting complex I, and stimulating ROS generation. To further support its mitochondrial effects, Mito-HNK oxidized mitochondrial peroxiredoxin-3 (Prx3) and suppressed the phosphorylated form of mitoSTAT3, which functions as a positive regulator of the mitochondrial electron transport chain through non-canonical STAT3 signaling in mitochondria (Yang and Rincon, 2016). Mito-HNK also effectively suppressed the invasion of NSCLC and SCLC cells. In vivo, low-dose Mito-HNK (3.75 μmol/kg) markedly suppressed the growth of NSCLC and SCLC lines in a lung orthotopic model and inhibited the growth and progression of lung cancer brain metastases. Within the brain metastases in mice, Mito-HNK induced mediators of cell death in the tumors, and it decreased pathways that support invasion and proliferation. In contrast, in the non-malignant stroma, Mito-HNK suppressed pathways that support metastatic lesions, including those involved in inflammation and angiogenesis. Even at doses 20-fold higher than those that were effective, Mito-HNK exhibited no toxicity in mice over 8 weeks of administration. Mito-HNK is therefore a safe agent that targets the metabolic vulnerabilities of primary and metastatic lung cancers. Its pronounced anti-invasive and anti-metastatic effects against brain metastases are particularly intriguing given the paucity of treatment options for such patients.

RESULTS

Synthesis and Toxicity of Mitochondria-Targeted HNK

Two Mito-HNKs were synthesized by reacting HNK with the bromodecyl-TPP⁺ cation, generating HNK with one TPP⁺ (Mito-HNK) or two TPP⁺ (bis-Mito-HNK) moieties (Figure 1A). The products were isolated by gel chromatography and purified by preparative high-performance liquid chromatography (HPLC), and their structures were characterized by nuclear magnetic resonance (NMR) and mass spectrometry (MS) (Figures S1–S3; Figure S3 related to Figure 1). To assess the potential toxicity of Mito-HNK, an 8-week subchronic toxicity study was conducted in A/J mice. As neurons and muscle cells may have a relatively high plasma membrane potential that might enhance the uptake of Mito-HNK, we used a modified Irwin screen that was developed as a comprehensive observational battery to broadly screen for central nervous system (CNS) and neuromuscular effects of agents (Irwin, 1968; Crawley, 2000). Modifications of this test are extensively used in the pharmaceutical industry and in academic research to identify many possible changes in neurological function (Lindgren et al., 2008; Crawley, 2000). The screen we used employed 35 distinct measurements to assess sensorimotor, neurological, and autonomic nervous system function (Olsen et al., 2010). We included mice treated with vehicle control and with various doses of Mito-HNK (7.5, 37.5, and 75 μmol/kg, which represent 2×, 10×, and 20× of the effective dose, respectively) (Figure 1B), given via oral gavage 5 days per week for 8 weeks. After 8 weeks of treatment, we did not observe any significant
differences between control mice and those treated with any dose of Mito-HNK, including the highest dose (75 μmol/kg) (Figures 1 B and 1 C; Table S1, related to Figure 1), for any of the 35 metrics tested. Furthermore, no histopathological changes were seen in either neural (frontal cortex and cerebellum) or muscle tissue (skeletal muscles including the soleus, plantaris, gastrocnemius, tibialis anterior, and quadriceps) (data not shown). Thus Mito-HNK did not show any indications of toxicity at a dose that is 20-fold higher than the effective dose.

Mito-HNK Inhibits Lung Cancer Cell Proliferation and Tumor Growth

Before conducting lung cancer brain metastases studies, in vitro studies compared the effects of Mito-HNK and bis-Mito-HNK on the proliferation of lung cancer brain metastatic H2030-BrM3 and PC9-BrM3 cells. Mito-HNK inhibits H2030-BrM3 lung cancer cell proliferation at significantly lower levels (IC_{50} = 0.26 μM) than HNK (IC_{50} = 27 μM) (Figure 2A). The double-substituted HNK analog (bis-Mito-HNK) is also significantly more potent than HNK (IC_{50} = 0.8 μM, Figure 2A), but not as potent as Mito-HNK. Because Bis-Mito-HNK has both hydroxyl groups substituted, it is unlikely to be easily metabolized to a quinone methide, suggesting other mechanism(s) of action. In subsequent experiments, we used the more potent mono-substituted analog, Mito-HNK. We verified that the more than 100-fold enhancement in anti-proliferative properties of Mito-HNK versus HNK is due to its targeting to mitochondria, because of the attached TPP^+ moiety. Liquid chromatography-mass spectrometry (LC-MS/MS) analysis of the fractions from H2030-BrM3 cells treated for 1 hr with 1 μM Mito-HNK showed mitochondrial accumulation of Mito-HNK (0.6 nmol versus 4.3 nmol in cytosolic versus mitochondrial fractions per 10^6 cells, respectively). Also, treatment of cells (0.1 μM, 24 hr) led to significantly higher mitochondrial accumulation of
Mito-HNK than HNK (Figure 2B). Combinations of HNK or decyl-HNK with Me-TPP⁺ (see Figure 2C for chemical structures) failed to reproduce the anti-proliferative effects of Mito-HNK (Figures 2D and 2E). Thus, attaching TPP⁺ to HNK markedly increases mitochondrial accumulation and anti-proliferative activity in lung cancer cells.

Next, we evaluated the efficacy of Mito-HNK in lung tumor growth using an orthotopic model of lung cancer in NOD/SCID mice. At 8 weeks of age, H2030-BrM3 (NSCLC) or DMS-273 (SCLC) cells were injected into
the left lung of mice. After 1 week, mice were treated by oral gavage 5 days per week with Mito-HNK (3.75 μmol/kg) or vehicle (corn oil). During the treatment, the progression of lung tumors was monitored by bioluminescence imaging. As shown in Figures 2F–2H, Mito-HNK (3.75 μmol/kg) reduced tumor size by ~70% (H2030-BrM3 cells) or ~40% (DMS-273 cells) when compared with control mice, whereas the same dose of HNK failed to decrease lung tumor growth (data not shown). However, in our previous study, a 10-fold higher dose of HNK (37.5 μmol/kg) was effective in decreasing lung tumor growth (Pan et al., 2017). Immunohistochemistry of serial sections showed a significant reduction in the proliferation marker Ki-67 in Mito-HNK-treated tumors (Figure 2I). Hematoxylin and eosin (H&E) staining did not reveal other morphological changes upon Mito-HNK treatment (Figure 2J).

**Mito-HNK Inhibits Invasion and Brain Metastasis of Lung Cancer Cells**

The Boyden chamber invasion assay, which was used to assess anti-metastatic potential, showed that Mito-HNK (48 hr) suppressed the in vitro invasion of both brain metastatic NSCLC lines in a dose-dependent manner (Figures 3A and 3C). Similarly, Mito-HNK inhibited the invasion of the SCLC line in a dose dependent manner (DMS-273) (Figures 3B and 3D) and was over 100-fold more potent than HNK (Pan et al., 2017). To rule out the possibility of pro-apoptotic or cytotoxic effects of Mito-HNK, the invasion assay was also conducted in lung cancer cells pretreated with Mito-HNK; as shown in Figure S4A; wells pretreated with Mito-HNK had significantly less cell invasion compared to control wells, while at these doses Mito-HNK did not cause significant cell death or pro-apoptotic activities, but rather blocked cell cycling machinery (Figures S4B and S4C, related to Figure 3), indicating that Mito-HNK directly inhibits cancer cell invasion.

To investigate the effect of Mito-HNK on in vivo metastasis, we used a previously characterized experimental lung cancer brain metastasis model to generate brain metastases in mice (Nguyen et al., 2009b; Pan et al., 2017). We generated green fluorescent protein (GFP)-luciferase-expressing variants of each lung cancer cell line (both NSCLC and SCLC) and confirmed that they efficiently formed brain metastases. We used an ultrasound-guided procedure to secure the precise injection of brain-seeking lung cancer cells into the left cardiac ventricle of NOD/SCID mice as described previously (Pan et al., 2017). These injected lung cancer cells rapidly colonized the cerebral and cerebellum, forming many nodules in animals treated with vehicle control (Figure 3F). Mito-HNK (3.75 μmol/kg) was administered by oral gavage starting 1 day after engrafting lung cancer cells in the arterial circulation; brain metastases were monitored by bioluminescence upon injection of luciferin. Mito-HNK inhibited the growth of lung cancer brain metastases of both NSCLC (H2030-BrM3) (Figure 3G) and SCLC (DMS-273) (Figure 3H) cells. Metastases were confirmed by ex vivo GFP imaging, H&E, and GFP immunostaining (Figure 3F). LC-MS analyses of brain extracts (Figure 3G) confirm that Mito-HNK crosses the BBB. These results show that Mito-HNK is a potent inhibitor of lung cancer brain metastases for both the NSCLC and SCLC models used.

**Mito-HNK Inhibits Complex I, Promotes ROS Generation, and Oxidizes Mitochondrial Peroxiredoxin-3**

We previously found that HNK blocks squamous cell lung cancer progression by inhibiting cellular respiration (or oxygen consumption rate [OCR]) and mitochondrial function (Pan et al., 2014). Here, we determined the effect of Mito-HNK on mitochondrial respiration. To test the activity on mitochondrial complexes, the cells were pretreated for 24 hr with Mito-HNK or HNK, followed by measuring the activities of mitochondrial respiratory complexes using the Seahorse XF96 extracellular flux analyzer. This approach provides high throughput, does not require cell fractionation, and can monitor the effect on complexes I and II in a single run. While establishing the model systems, we observed that rotenone (complex I inhibitor) blocks OCR, which can be restored by adding succinate (complex II substrate), whereas in the presence of malonate (complex II inhibitor), the addition of succinate does not stimulate OCR (Figure S5, related to Figure 4). Antimycin A (complex III inhibitor) decreases both pyruvate- and succinate-driven OCR. These studies established the validity of these mitochondrial complex assays, in agreement with the published protocol (Salabei et al., 2014). Next, we compared the ability of HNK and Mito-HNK to inhibit mitochondrial complex I in H2030-BrM3 and DMS-273 cell lines. Mito-HNK was greater than 100-fold more potent than HNK in inhibiting complex I both in H2030-BrM3 (Figure 4A) and DMS-273 (Figure 4B) cells.

We hypothesized that inhibition of mitochondrial complex I by Mito-HNK would lead to increased ROS levels in lung cancer cells. Indeed, 2-OH-E⁺⁺, the O₂⁻⁻*-specific product of hydroethidine (HE) oxidation, was significantly increased in H2030-BrM3 and DMS-723 cells treated with Mito-HNK (Figures 4C, 4D, and S6; Figure S6 related to Figure 4). A strong induction of one-electron oxidation of HE with the
Figure 3. Mito-HNK Inhibits Invasion and Brain Metastasis of Lung Cancer Cells

(A and C) The anti-invasive effects of Mito-HNK on NSCLC lines H2030-BrM3 and PC9-BrM3 were assessed via the Boyden chamber invasion assay after 48-hr treatment. Representative images are shown in (A) and the quantitative data are shown in (C, *P < 0.05, **P < 0.01, ***P < 0.001 vs control).

(B and D) Representative images (B) and quantitative data (D) of the invasion assay for SCLC DMS-273 cells indicate that Mito-HNK is at least 100-fold more potent than HNK (*P < 0.05, **P < 0.01 vs control).

(E) High-resolution echocardiography to visualize the needle position within the left cardiac ventricle, for injecting lung cancer cells in the in vivo experiments to establish brain metastases.

(F) Representative bioluminescence, GFP expression, and H&E staining images of brains taken from control, HNK, and Mito-HNK (3.75 μmol/kg each) mice.
Mitochondrial DNA Depletion Abrogates Mito-HNK’s Effect on Cancer Cell Proliferation

Mitochondria are vital organelles and the powerhouse of eukaryotic cells. mtDNA, encodes for 13 proteins of the ~1,500 total that comprise the mitochondrial proteome. All 13 mtDNA-encoded proteins are sub-units of mitochondrial respiratory complexes and are therefore critical for the bioenergetic machinery. Mutations and copy number changes in mtDNA are often linked with cancer development. A recent study showed that tumor cells without mtDNA (ρ0 cells) have delayed tumor growth (Tan et al., 2015; Dong et al., 2017), and the transfer of intact mitochondria with their mtDNA from host cells to the tumor cells can restore the tumor cells’ respiration and tumor formation efficacy. To delineate the involvement of mitochondria in Mito-HNK’s anti-cancer effects, we tested Mito-HNK in these same ρ0 cells. ρ0 Cells showed no mitochondrial complex I and complex II activities compared with parental cells (Figures 5A and 5B, left panels), which is consistent with the absence of mitochondria in ρ0 cells. PicoGreen DNA staining revealed a complete loss of mtDNA in both ρ0 cell lines (Figures 5A and 5B, right panel, bottom row, arrows). In contrast, the parental lines that had mitochondria showed numerous cytoplasmic green punctae located within the mitochondrial fibrillar network (Figures 5A and 5B, right panel, top row, arrows) representing mtDNA nucleoids that co-localized with MitoTracker Deep Red staining. Mito-HNK treatment inhibited cell proliferation in both parental cell lines by >50% (Figures 5C and 5D), but showed only minimal effects on both ρ0 cell lines, indicating that loss of mitochondrial function abrogates the anti-proliferative effects of Mito-HNK. We further validated these findings using another approach, i.e., depleting host mtDNA with a truncated form of a viral UL12.5 gene (Figure S10, related to Figure 5). These results strongly suggest that the anti-cancer effects of Mito-HNK are dependent on mitochondrial function.

Role of mitoSTAT3 in Mediating the Effects of Mito-HNK on Lung Cancer Cells

Potential additional components of the mechanism by which Mito-HNK inhibits lung cancer brain metastasis were examined via the PathScan RTK Signaling Antibody Array (Figure S8A, related to Figure 6), which has been used extensively to study mechanisms of candidate cancer drugs (Pan et al., 2017; Vazquez-Martin et al., 2013). This array identified mitoSTAT3 as a potential target of Mito-HNK (Figure 6A). We validated the effects of Mito-HNK on mitoSTAT3 phosphorylation in lung cancer cells via western blot (Figures 6B and S8B; Figure S8B related to Figure 6). Since AMPK and mitoSTAT3 can play important roles in regulating mitochondrial activity, apoptosis, proliferation, and migration (Sobotta et al., 2015; Feng et al., 2014; Liu et al., 2003; Zhang et al., 2013; Wen et al., 1995), we examined the effects of Mito-HNK on AMPKThr172 and mitoSTAT3Ser727 phosphorylation by western blot (Figure 6B). Compared with HNK, Mito-HNK induced much stronger AMPK phosphorylation and potently inhibited mitoSTAT3Ser727 phosphorylation in both PC9-BrM3 and H2030-BrM3 cells. We then used the clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein (Cas9) system to knock out STAT3 (Figure 59, related to Figure 6). Cell lines were screened by polymerase chain reaction (PCR) and sequencing, and knockouts were confirmed by western blotting (Figure 6C). CRISPR significantly decreased STAT3 protein by >80% (Figure 6D), and the anti-invasive and anti-proliferation effects of Mito-HNK (24 hr) were abrogated in the STAT3-deficient cells (Figures 6D and 6E). However, no direct binding of Mito-HNK to STAT3 was detected (not shown) using an anti-TPP+ antibody (obtained from Dr. Michael P. Murphy, Mitochondrial Biology Unit, Cambridge, UK).
Pathway Analysis of the Downstream Mediators of Mito-HNK Therapy

As shown in Figure 3, Mito-HNK treatment for 4 weeks dramatically reduced the brain metastatic burden of H2030-BrM3 cells. We used SSRS (species-specific RNAseq analysis) to profile the gene expression changes in the H2030-BrM3 brain metastatic lesions remaining after 4 weeks of Mito-HNK treatment compared with the brain metastatic lesions in vehicle-treated control animals. The H2030-BrM3 cells remaining in the brain metastatic lesions of Mito-HNK-treated animals had 4,660 differentially expressed (DE) genes (false discovery rate [FDR] <0.05) compared with vehicle-treated animals (Table S2; related to Figure 7). The nonmalignant stroma of the remaining brain metastatic lesions in Mito-HNK-treated animals had 6,544 DE genes (FDR <0.05) compared with the vehicle-treated mice (Table S3, related to Figure 7), of which only 22% (1,444 DE genes) overlapped with DE genes in the human malignant cells. We used the Ingenuity IPA tool (Qiagen, Redwood City, CA) to assess the biological and molecular pathways that were differentially regulated between the malignant tumor cells and the nonmalignant stroma.
Mito-HNK treatment strongly induced mediators of cell death (Z score: +2.5; p < 10^-57) in the human malignant H2030-BrM3 cells but not in the nonmalignant stroma (Figure 7A), indicating that the pro-apoptotic effects of Mito-HNK are largely specific to the malignant tumor. In addition, Mito-HNK treatment also significantly downregulated the pathways involved in tumor invasion and proliferation and altered multiple molecular pathways that have been implicated in all three cellular processes (Figure 7B).

Figure 5. Depletion of mtDNA Abrogates the Anti-Proliferative Effects of Mito-HNK in Lung Cancer Cells
(A and B) Validation of the loss of activities of the mitochondrial complexes in \( \rho^0 \) cells. (A and B, left panels) Permeabilized cells were assayed in medium containing 10 mM pyruvate and 1.5 mM malate (substrates for complex I) in mannitol and sucrose (MAS) buffer. The complex I-related oxygen consumption rate (OCR) was assayed immediately and verified by injecting rotenone (complex I inhibitor) as indicated. Then, complex II-related OCR was measured by supplying cells with succinate (substrate for complex II, 10 mM). Both malonate (complex II inhibitor, 10 mM) and antimycin A (complex III inhibitor, 20 \( \mu \)M) were injected where indicated. (A and B, right panels) Validation of the absence of mitochondria in \( \rho^0 \) cells with PicoGreen staining for mtDNA. Arrows indicate mitochondria fibrillar network.
(C and D) mtDNA depletion abrogates the anti-proliferative effects of Mito-HNK (0.4 \( \mu \)M, 48 hr) in both B16 and 143B \( \rho^0 \) cells. (***P < 0.001 vs. B16 or 143b parental cells). Error bars indicate SD.
In comparison, the nonmalignant stroma of the H2030-BrM3 brain lesions in Mito-HNK-treated mice had significant downregulation of inflammatory and angiogenic pathways, as well as altered expression of multiple key pathways that contribute to these processes (Figure 7C). Collectively, these data suggest that, in addition to Mito-HNK’s pro-apoptotic and anti-proliferative effects on the tumor cells, Mito-HNK also inhibits stromal cell pathways that typically support the formation and progression of metastatic lesions in the brain.

**DISCUSSION**

Although higher dose of HNK can induce mitochondria-dependent apoptosis in cancer cells (Lin et al., 2012; Pan et al., 2014; Martin et al., 2013), it is not specifically sequestered into cell mitochondria. By conjugating HNK with TPP⁺ to generate Mito-HNK, we markedly enhanced mitochondrial accumulation and the ability to block proliferation and invasion of brain metastatic human lung cancer cells. Low micromolar levels of Mito-HNK inhibit complex I, stimulate ROS, oxidize mitochondrial Prx3, and suppress mitoSTAT3Ser727 phosphorylation. These findings provide the first evidence that, by directly targeting mitochondrial complex I, Mito-HNK can have exceptional preventive and therapeutic efficacy to inhibit lung cancer growth and brain metastasis.

Mito-HNK (at 3.75 µmol/kg) significantly inhibited lung cancer metastases from growing in the brain, whereas this same dose of HNK does not inhibit brain metastasis. A 10-fold higher dose of HNK (37.5 µmol/kg, which equals to 10 mg/kg) is needed to inhibit brain metastasis (Pan et al., 2014, 2017). Mito-HNK (3.75 µmol/kg) also inhibited lung tumor growth in orthotopic models of both NSCLC and SCLC. These results are consistent with the markedly greater potency and efficacy of Mito-HNK in inhibiting proliferation, migration, and invasion of lung cancer cells. These results further suggest that Mito-HNK can be effective regardless of the driver mutation status (mutant EGFR in PC9-BrM3 cells; mutant KRAS in H2030-BrM3 cells). Therefore this study constitutes a critical step toward the clinical translation of Mito-HNK for treating lung cancer and its metastases.

The constitutive activation (phosphorylation) of STAT3 in many tumors is important for tumor growth, survival, progression (Foli and Camporeale, 2015), and metastasis (Kamran et al., 2013). Our data imply that
mitoSTAT3 is another important molecular target of Mito-HNK. Mito-HNK (0.2 μM) suppressed the phosphorylation of STAT3 at Ser727 (Figure 6), and STAT3 knockout abrogated its anti-invasive effects (Figures 6D and 6E). Phosphorylation of STAT3 on Tyr705 promotes its nuclear translocation and its canonical activity as a transcription factor (Sobotta et al., 2015; Feng et al., 2014; Liu et al., 2003; Zhang et al., 2013; Wen et al., 1995). Phosphorylation at Ser727 also has important mitochondrial implications that are independent of its transcriptional role (Poli and Camporeale, 2015; Yang and Rincon, 2016). MitoSTAT3 can inhibit the mitochondrial permeability transition pore and can promote optimal electron transport (Poli and Camporeale, 2015; Wegrzyn et al., 2009; Szczepanek et al., 2011). The effects of p-STAT3 Ser727 on mitochondrial electron transport may not be direct, however, given that complexes I and II are about 105 more abundant than mitoSTAT3 (Phillips et al., 2010). Of particular note, p-STAT3 Ser727 can promote complex I activity and the transformation and growth of multiple cancers (Yu et al., 2015; Gough et al., 2009; Zhang et al., 2013; Capron et al., 2014). These effects are not dependent on p-STAT3 Tyr705 (Yu et al., 2015; Gough et al., 2009; Zhang et al., 2013; Capron et al., 2014). The suppression of p-STAT3 Ser727 could therefore be important for Mito-HNK’s ability to suppress lung tumor growth, invasion, and metastasis. Cancer
metastasis is a complex, multistep process including cell proliferation, invasion, self-renewal, and tumor cell immune evasion. Compelling evidence published in recent years has demonstrated that STAT3 activation plays a critical role in every step of metastasis (Devarajan and Huang, 2009). Activated STAT3 could directly bind to the promoter of MMP (matrix metalloproteinases) genes, increase the expression of multiple MMPs, and lead to the extracellular matrix formation, ultimately promote cellular invasion (Dechow et al., 2004; Xie et al., 2004; Itoh et al., 2006; Li et al., 2011). Furthermore, STAT3 also modulates Rac1 or Rho activity to maintain directional persistence during migration (Debidda et al., 2005; Teng et al., 2009). STAT3 activation also upregulates the secretion of various immunosuppressive factors such as interleukin-6 and tumor necrosis factor-α (Nguyen et al., 2009a) and reduces the activity of NK cells (Wang et al., 2004), and thereby protecting tumor cells during circulation.

Although there are multiple events by which Mito-HNK might function to decrease p-STAT3Ser727, it is unlikely that Mito-HNK directly affects STAT3, as no direct binding of Mito-HNK to STAT3 was detected. Rather, the data suggest that complex I inhibition, which occurs within minutes of Mito-HNK treatment, is upstream of the effects on mitoSTAT3. Specifically, Mito-HNK still inhibited complex I in cells in which STAT3 was knocked down (not shown), indicating that STAT3 is not required for complex I inhibition. Based on the data, we postulate a mechanism (Figure 8) in which complex I inhibition is a key initiating event that promotes the other observed effects. It is well recognized that complex I inhibition can stimulate mitochondrial ROS generation, consistent with the ROS data (Figures 4C and 4D) and the selective oxidation of mitochondrial Prx3 (Figures 4E and 4F). Since Prx3 represents ~90% of total mitochondrial peroxidase activity (Cox et al., 2009), these data indicate that Mito-HNK-induced ROS generation overwhelms the mitochondrial capacity to degrade peroxides. STAT3 is susceptible to oxidative inactivation (Li et al., 2010; Shaw, 2010), and the levels of active p-STAT3Ser727 can be enhanced by antioxidants (e.g., glutathione, N-acetylcysteine) (Capron et al., 2014). Although peroxides might conceivably oxidize STAT3 directly (Li et al., 2010), it is unlikely that STAT3 thios would initially compete with Prxs for cellular H₂O₂ given the highly favorable kinetics of Prxs (Cox et al., 2009). Oxidized Prxs can oxidize various proteins (Bindoli et al., 2008; Forman et al., 2010, 2014), including STAT3 (Sobotta et al., 2015), so pronounced Prx3 oxidation in Mito-HNK-treated cells is a logical link between enhanced mitochondrial ROS generation and inhibiting mitoSTAT3 function.

We have shown that the increased in vitro potency of Mito-HNK over HNK is clear, and the antitumor activity of Mito-HNK in the in vivo tumor models (Figures 2F–2H and 3F–3H) is impressive. Our observation that the compound has limited effects on normal cells or tissues (Figure 1) is most likely due to the unusually greater uptake and retention of mito-targeted compounds by cancer cells as a consequence of highly elevated mitochondrial and plasma membrane potentials. Thus the preferential accumulation of Mito-HNK in the mitochondria of cancer cells leads to highly potent anti-cancer effects with no observed toxicity in mice given 20-fold more than the
effective dose for 8 weeks. Similarly, other mitochondria-targeted agents are less toxic to normal cells than
tumorigenic cells (Modica-Napolitano and Aprille, 2001; Cheng et al., 2013) and show no adverse effects
with long-term administration in mice and humans (Gane et al., 2010; McManus et al., 2011). Combining
Mito-HNK with standard chemotherapeutics, such as cisplatin, could significantly increase the killing of cancer
cells and, meanwhile, lower the effective doses of these chemotherapeutics (Figure S11, related to Figure 3).
The low toxicity of Mito-HNK, coupled with its ability to cross the BBB and the blood-CSF barrier (Wang et al.,
2011; Lin et al., 2012), make it a highly attractive therapeutic agent, alone or in combination with standard ther-
apy, for lung cancer and its metastases to the brain.

The SSRS analysis of brain metastatic H2030-BrM3 cells in treated mice further demonstrate the on-target
antitumor effects of Mito-HNK to activate cell death and anti-proliferative signaling pathways in the met-
astatic tumor cells (Figures 7A and 7B), whereas similar pathways were not induced in the nonmalignant
stromal cells (Figures 7A and 7C). In the nonmalignant stroma, Mito-HNK significantly attenuated inflam-
matory and pro-angiogenic pathways (Figure 7C), which resembles similar stromal-dependent antitumor
mechanisms reported for HNK (Kim and Cho, 2008; Bai et al., 2003). Thus Mito-HNK is substantially
more potent than HNK in targeting tumor cell mitochondria while maintaining its ability to suppress key
components of the tumor stroma that can promote malignancy.

In summary, we demonstrate here the pronounced anti-cancer and anti-metastatic potential of
Mito-HNK using both in vitro and in vivo lung cancer models. Mito-HNK potently inhibits orthotopic
lung tumor growth as well as lung cancer metastasis to the brain. Mechanistically, we discovered, for
the first time, that the ability of Mito-HNK to concentrate in the mitochondria renders it highly effective
at inhibiting complex I, which corresponds with its ability to enhance mitochondrial ROS genera-
tion, promote Prx3 oxidation, suppress the phosphorylation of mitoSTAT3, and suppress the prolifera-
tion and invasion of cancer cells. The low toxicity of Mito-HNK, coupled with its ability to cross the
BBB, makes it a highly attractive preventive and therapeutic agent for lung cancer and its brain metas-
tases. Targeting of cancer cell mitochondrial bioenergetics represents a new strategy for treating lung
cancer.

METHODS
All methods can be found in the accompanying Transparent Methods supplemental file.

Patent
PCT/US2016/036827 “Mito-Honokiol Compounds and Methods of Synthesis and Use Thereof”.

DATA AND SOFTWARE AVAILABILITY
The authors declare that all data supporting the findings of this study are available within the article and its
Supplemental Information, and from the corresponding author upon reasonable request. The RNA-seq raw
sequence reads data from the H2030-BrM3 brain metastatic lesions of nude mice treated with Mito-HNK or
vehicle control for four weeks (n = 3 per group, total N = 6) as described in the Supplementary file have
been deposited in the Sequence Read Archive under accession number of SRP144372. Mito-HNK will be
freely distributed upon request to qualified academic investigators for non-commercial research. Primary
or luciferase-tagged cancer cells will be distributed following completion of a material transfer agreement
agreed upon by the Medical College of Wisconsin and the recipient organization. Costs to ship Mito-HNK
or cancer cell lines generated by this project will be incurred by the requestor and will be shipped following
all Federal guidelines and precautions to minimize loss.

SUPPLEMENTAL INFORMATION
Supplemental Information includes Transparent Methods, 11 figures, and 3 tables and can be found with
this article online at https://doi.org/10.1016/j.isci.2018.04.013.

ACKNOWLEDGMENTS
We are grateful to Dr. Joan Massage (Memorial Sloan Kettering Cancer Center) for providing the H2030-
BrM3 and PC9-BrM3 cells, to O.V. (Roskilde University) for providing the 143B and 143B p0 cells, and to M.B.
(Czech Academy of Sciences) for providing the B16 and B16 p0 cells. This work was funded by the NIH grant
R01CA208648.
AUTHOR CONTRIBUTIONS

M.Y., B.K., J.P., and J.Z. were responsible for the overall experimental design with input from Y.L., G.C., D.X., M.F., C.M.O., and C.R.M. The project was supervised by M.Y., B.K., J.P., and J.Z. M.H. synthesized and characterized the mito-honokiol. C.M.O., J.P., and O.V. assessed the animal toxicity of Mito-HNK. G.C., J.P., and Y.L. did the cell proliferation and transwell invasion studies. J.P. and Y.L. did the tyrosine kinase assays, western blots, and STAT3 knockout and knockdown experiments. J.P., Y.L., Q.Z., and Y.W. conducted the orthotopic lung cancer and brain metastasis animal studies. M.F., D.X., and S.-W.T. did the RNA-seq analysis. J.P. and G.C. conducted the experiments with p60 cells. G.C. and J.Z. analyzed respiratory enzyme activity and intracellular oxidants. C.R.M. did the peroxiredoxin experiments. M.B., O.V., and J.N. provided rho0 or rho cells. M.Y. and B.K. acquired the funding. The following were largely responsible for writing, reviewing, and editing the manuscript: J.P., G.C., J.Z., M.H., M.F., C.R.M., B.K., and M.Y.

DECLARATION OF INTERESTS

The authors declare that there are no financial or other conflicts of interest.

Received: December 8, 2017
Revised: March 13, 2018
Accepted: April 16, 2018
Published: May 25, 2018

REFERENCES

Arora, S., Singh, S., Piazza, G.A., Contreras, C.M., Panyam, J., and Singh, A.P. (2012). Honokiol: a novel natural agent for cancer prevention and therapy. Curr. Mol. Med. 12, 1244–1252.

Asin-Cayuela, J., Manas, A.R.B., James, A.M., Smith, R.A.J., and Murphy, M.P. (2004). Fine-tuning the hydrophobicity of a mitochondria-targeted antioxidant. FEBS Lett. 571, 9–16.

Bai, X., Cerimele, F., Ushio-Fukai, M., Waqas, M., Campbell, P.M., Gounderajan, B., Der, C.J., Battle, T., Frank, D.A., Ye, K., et al. (2003). Honokiol, a small molecular weight natural product, inhibits angiogenesis in vitro and tumor growth in vivo. J. Biol. Chem. 278, 35501–35507.

Berridge, M.V., Dong, L., and Neuzil, J. (2015). Mitochondrial DNA in tumor initiation, progression, and metastasis: role of horizontal mtDNA transfer. Cancer Res. 75, 3203–3208.

Bindoli, A., Fukuto, J.M., and Forman, H.J. (2008). Thiol chemistry in peroxidase catalysis and redox signaling. Antioxid. Redox Signal. 10, 1549–1564.

Capron, C., Jondeau, K., Casetti, L., Jalbert, V., Costa, C., Verheugen, E., Masse, J.M., Coppo, P., Bene, M.C., Bourdoncle, P., et al. (2014). Viability and stress protection of chronic lymphoid leukemia cells involves overactivation of mitochondrial phosphoSTAT3Ser727. Cell Death Dis. 5, e1451.

Cheng, G., Zielonka, J., Dronka, B.P., Mcallister, D., Mackinnon, A.C., Jr., Joseph, J., and Kalyanaraman, B. (2012). Mitochondria-targeted drugs synergize with 2-deoxyglucose to trigger breast cancer cell death. Cancer Res. 72, 2634–2644.

Cheng, G., Zielonka, J., Mcallister, D., Hardy, M., Ouari, O., Joseph, J., Dronka, M.B., and Kalyanaraman, B. (2015). Antiproliferative effects of mitochondria-targeted cationic antioxidant analogs and analogs: role of mitochondrial bioenergetics and energy-sensing mechanism. Cancer Lett. 365, 96–106.

Cheng, G., Zielonka, J., Mcallister, D., Tsai, S., Dronka, M.B., and Kalyanaraman, B. (2014). Profiling and targeting of cellular bioenergetics: inhibition of pancreatic cancer cell proliferation. Br. J. Cancer 111, 85–93.

Cheng, G., Zielonka, J., Mcallister, D.M., Mackinnon, A.C., Jr., Joseph, J., Dronka, M.B., and Kalyanaraman, B. (2013). Mitochondria-targeted vitamin E analogs inhibit breast cancer cell energy metabolism and promote cell death. BMC Cancer 13, 285.

Cox, A.G., Winterbourn, C.C., and Hampton, M.B. (2009). Mitochondrial peroxiredoxin involvement in antioxidant defence and redox signalling. Biochem. J. 425, 313–325.

Crawley, J.N. (2000). What’s Wrong with My Mouse? Behavioral Phenotyping of Transgenic and Knockout Mice (Wiley-Liss).

Debidlda, M., Wang, L., Zang, H., Poli, V., and Zheng, Y. (2005). A role of STAT3 in Rho GTPase-regulated cell migration and proliferation. J. Biol. Chem. 280, 17273–17285.

Dechow, T.N., Pedrizzini, L., Leitch, A., Leslie, K., Gerald, W.L., Linkov, I., and Bromberg, J.F. (2004). Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-C. Proc. Natl. Acad. Sci. USA 101, 10602–10607.

Devarajan, E., and Huang, S. (2009). STAT3 as a central regulator of tumor metastases. Curr. Mol. Med. 9, 626–633.

Dong, L.F., Kovarov, J., Bajzikova, M., Bezawork-Geleta, A., Svec, O., Endaya, B., Sachaphibulkij, K., Coelho, A.P., Sekova, N., Ruzickova, A., et al. (2017). Horizontal transfer of whole mitochondria restores tumorigenic potential in mitochondrial DNA-deficient cancer cells. Elife 6, e22187.

Feng, Y., Ke, C., Tang, Q., Dong, H., Zheng, X., Lin, W., Ke, J., Huang, J., Yeung, S.C., and Zhang, H. (2014). Metformin promotes autophagy and apoptosis in esophageal squamous cell carcinoma by downregulating Stat3 signaling. Cell Death Dis. 5, e1088.

Finchii, P.G., Larsen, D.S., Evans, C., Larsen, L., Bright, T.P., Robb, E.L., Trinka, J., Prime, T.A., James, A.M., Smith, R.A.J., et al. (2015). A mitochondria-targeted derivative of ascorbate: MitoC. Free Radic. Biol. Med. 89, 668–678.

Forman, H.J., Maiorino, M., and Ursini, F. (2010). Signaling functions of reactive oxygen species. Biochemistry 49, 835–842.

Forman, H.J., Ursini, F., and Maiorino, M. (2014). An overview of mechanisms of redox signaling. J. Mol. Cell Cardiol. 73, 2–9.

Gane, E.J., Weilert, F., Orr, D.W., Keogh, G.F., Gibson, M., Lockhart, M.M., Frampton, C.M., Taylor, K.M., Smith, R.A., and Murphy, M.P. (2010). The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients. Liver Int. 30, 1019–1026.

Goldberg, S.B., Contessa, J.N., Omay, S.B., and Chiang, V. (2015). Lung cancer brain metastases. Cancer J. 21, 398–403.

Gough, D.J., Corlett, A., Schliesinger, K., Wegryn, J., Larner, A.C., and Levy, D.E. (2009). Mitochondrial STAT3 supports Ras-dependent oncogenic transformation. Science 324, 1713–1716.

Irwin, S. (1968). Comprehensive observational assessment: Ia. a systematic, quantitative procedure for assessing the behavioral and
physiologic state of the mouse. Psychopharmacology 13, 222–257.
Itoh, M., Murata, T., Suzuki, T., Shindo, M., Nakajima, K., Imai, K., and Yoshida, K. (2008). Requirement of STAT3 activation for maximal collagenase-1 (MMP-1) induction by epidermal growth factor and malignant characteristics in T24 bladder cancer cells. Oncogene 25, 1195–1204.
Kamran, M.Z., Patil, P., and Gude, R.P. (2013). Role of STAT3 in cancer metastasis and translational advances. Biomed. Res. Int. 2013, 421821.
Kim, B.H., and Cho, J.Y. (2008). Anti-inflammatory effect of honokiol is mediated by PI3K/Akt pathway suppression. Acta Pharmacol. Sin. 29, 113–122.
Lampidis, T.J., Hasin, Y., Weiss, M.J., and Chen, L.B. (1989). Selective killing of carcinoma cells in vitro by lipophilic-cationic compounds: a cellular basis. Biomed. Pharmacother. 39, 220–226.
Li, H., Huang, C., Huang, K., Wu, W., Jiang, T., Cao, J., Feng, Z., and Gius, Z. (2011). STAT3 expression in nude mice. PLoS One 6, e222–257.
Lin, J.W., Chen, J.T., Hong, C.Y., Lin, Y.L., Wang, Y., and You, M. (2016). Honokiol inhibits lung cancer cell invasiveness and matrix metalloproteinase-7 expression in vitro by lipophilic-cationic compounds: a cellular basis. Biomed. Pharmacother. 39, 302–314.
Lindgren, S., Bass, A.S., Brscic, R., Bruse, K., Friedrichs, G.S., Kallman, M.J., Markgraf, C., Patmore, L., and Pugsley, M.K. (2008). Benchmarking safety pharmacology regulatory packages and best practice. J. Pharmacol. Toxicol. Methods 58, 99–109.
Liu, H., Ma, Y., Cole, S.M., Zander, C., Chen, K.H., Karra, J., and Pope, R.M. (2003). Serine phosphorylation of STAT3 is essential for Mcl-1 expression and macrophage survival. Blood 102, 344–352.
Madar, I., Anderson, J.H., Szabo, Z., Scheffel, U., Kao, P.F., Ravert, H.T., and Dannals, R.F. (1999). Enhanced uptake of [11C]CTMP in canine brain tumor: a PET study. J. Nucl. Med. 40, 1180–1185.
Martin, S., Lamb, H.K., Brady, C., LeKoffice, B., Bonner, M.Y., Thompson, P., Lovat, P.E., Arbor, J.L., Hawkins, A.R., and Redfern, C.P. (2013). Inducing apoptosis of cancer cells using small-molecule plant compounds that bind to GRP78. Mol. Cancer 12, 635–540.
Modica-Napolitano, J.S., and Aprille, J.R. (2001). Delocalized lipophilic cations selectively target the mitochondria of carcinoma cells. Adv. Drug Deliv. Rev. 49, 63–70.
Murphy, M.P. (2016). Understanding and preventing mitochondrial oxidative damage. Biochem. Soc. Trans. 44, 1219–1226.
Murphy, M.P., and Smith, R.A. (2007). Targeting antioxidants to mitochondria by conjugation to lipophilic cations. Annu. Rev. Pharmacol. Toxicol. 47, 629–656.
Nguyen, D.X., Bos, P.D., and Massague, J. (2009a). Metastasis from dissemination to organism-specific colonization. Nat. Rev. Cancer 9, 274–284.
Nguyen, D.X., Chiang, A.C., Zhang, X.H., Kim, J.Y., Kris, M.G., Ladanyi, M., Gerald, W.L., and Massague, J. (2009b). WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell 138, 51–62.
Olsen, C.M., Childs, D.S., Stanwood, G.D., and Winder, D.G. (2010). Operant sensation seeking requires metabolotropic glutamate receptor 5 (mGluRs). PLoS One 5, e13085.
Pan, J., Lee, Y., Wang, Y., and You, M. (2016). Honokiol targets mitochondria to halt cancer progression and metastasis. Mol. Nutr. Food Res. 60, 1383–1395.
Pan, J., Lee, Y., Zhang, G., Xiong, D., Wan, T.C., Wang, Y., and You, M. (2017). Honokiol decreases lung cancer metastasis through inhibition of the STAT3 signaling pathway. Cancer Prev. Res. (Phila.) 10, 133–141.
Pan, J., Zhang, Q., Liu, Q., Komas, S.M., Kalyanaraman, B., Lubet, R.A., Wang, Y., and You, M. (2014). Honokiol inhibits lung tumorigenesis through inhibition of mitochondrial function. Cancer Prev. Res. (Phila.) 7, 1149–1159.
Philips, D., Reilly, M.J., Aponte, A.M., Wang, G., Boja, E., Guzek, M., and Balaban, R.S. (2010). Stoichiometry of STAT3 and mitochondrial proteins: implications for the regulation of oxidative phosphorylation by protein-protein interactions. J. Biol. Chem. 285, 23532–23536.
Planchard, D., and Giroux Leprieur, E. (2011). [Biomarkers and targeted therapies in non-small cell lung cancer: present and future treatments]. Rev. Pneumol Clin. 67 (Suppl 1), S36–540.
Poli, V., and Camporeale, A. (2015). STAT3-Mediated metabolic reprogramming in cellular transformation and implications for drug resistance. Front. Oncol. 5, 121.
Rideout, D.C., Calogeropoulos, T., Jaworski J.S., Dagnino, R.J., Jr., and McCarty, M.R. (1989). Phosphonium salts exhibiting selective anti-carcinoma activity in vitro. Anticancer Drug Des. 4, 265–280.
Ross, M.F., Prime, T.A., Abakumova, I., James, A.M., Porteous, C.M., Smith, R.A.J., and Murphy, M.P. (2008). Rapid and extensive uptake and activation of hydrophobic triphenylphosphonium cations within cells. Biochem. J. 411, 633–645.
Salabei, J.K., Gibb, A.A., and Hill, B.G. (2014). Comprehensive measurement of respiratory activity in permeabilized cells using extracellular flux analysis. Nat. Protoc. 9, 421–438.
Shaw, P.E. (2010). Could STAT3 provide a link between respiration and cell cycle progression? Cell Cycle 9, 4294–4296.
Smith, R.A., Porteous, C.M., Kane, A.M., and Murphy, M.P. (2003). Delivery of bioactive molecules to mitochondria in vivo. Proc. Natl. Acad. Sci. USA 100, 5407–5412.
Smith, R.A.J., Hartley, R.C., Cochemé, H.M., and Murphy, M.P. (2012). Mitochondrial pharmacology. Trends Pharmacol. Sci. 33, 341–352.
Smith, R.A.J., and Murphy, M.P. (2010). Animal and human studies with the mitochondria-targeted antioxidant MitoQ. Annu. N.Y. Acad. Sci. 1201, 96–103.
Snow, B.J., Rolle, F.L., Lockhart, M.M., Frampton, C.M., O’Sullivan, J.D., Fung, V., Smith, R.A.J., Murphy, M.P., and Taylor, K.M. (2010). A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson’s disease. Mov. Disord. 25, 1670–1674.
Sobotta, M.C., Liou, W., Stocker, S., Talwar, D., Oehler, M., Ruppert, T., Scharf, A.N., and Dick, T.P. (2015). Peroxiredoxin-2 and STAT3 form a redox relay for H2O2 signaling. Nat. Chem. Biol. 11, 64–70.
Summerhayes, I.C., Lampidis, T.J., Bernal, S.D., Nadakavukaren, J.J., Nadakavukaren, K.K., Shepherd, E.L., and Chen, L.B. (1982). Unusual retention of rhodamine 123 by mitochondria in muscle and carcinoma cells. Proc. Natl. Acad. Sci. USA 79, 5292–5296.
Szczepanek, K., Chen, Q., Derecka, M., Salloum, F.N., Zhang, Q., Szelag, M., Cichy, J., Kukreja, R.C., Dulak, J., Lesniewski, E.J., et al. (2011). Mitochondrial-targeted Signal transducer and activator of transcription 3 (STAT3) protects against ischemia-induced changes in the electron transport chain and the generation of reactive oxygen species. J. Biol. Chem. 286, 29610–29620.
Tan, A.S., Baty, J.W., Dong, L.F., Bezawork-Geleta, A., Endaya, B., Goodwin, J., Bajzova, M., Kovarova, J., Peteka, M., Yan, B., et al. (2015). Mitochondrial genome acquisition restores respiratory function and tumorigenic potential of cancer cells without mitochondrial DNA. Cell Metab. 21, 81–94.
Tauskela, J.S. (2007). MitoQ—a mitochondria-targeted antioxidant. Idrugs 10, 399–412.
Teng, T.S., Lin, B., Manser, E., Ng, D.C., and Cao, X. (2009). STAT3 promotes directional cell migration by regulating Rac1 activity via its activator betaPIF. J. Cell Sci. 122, 4150–4159.
Vazquez-Martín, A., Culi, S., Oliveras-Ferrarás, C., Torres-García, V.Z., Corrales-Baja, B., Cuyás, E., Bonavia, R., Visa, J., Martín-Castillo, B., Barrañon-Catalán, E., et al. (2013). IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing
effect of EGFR exon 19 deletion mutations. Sci. Rep. 3, 2560.

Wang, T., Niu, G., Kortylewski, M., Burdelya, L., Shain, K., Zhang, S., Bhattacharya, R., Gabrilovich, D., Heller, R., Coppola, D., et al. (2004). Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat. Med. 10, 48–54.

Wang, X., Duan, X., Yang, G., Zhang, X., Deng, L., Zheng, H., Deng, C., Wen, J., Wang, N., Peng, C., et al. (2011). Honokiol crosses BBB and BCSFB, and inhibits brain tumor growth in rat 9L intracerebral gliosarcoma model and human U251 xenograft glioma model. PLoS One 6, e18490.

Wegrzyn, J., Potla, R., Chwae, Y.J., Sepuri, N.B., Zhang, Q., Koeck, T., Derecka, M., Szczepanek, K., Szlag, M., Gornicka, A., et al. (2009). Function of mitochondrial Stat3 in cellular respiration. Science 323, 793–797.

Weinberg, F., Hamanaka, R., Wheaton, W.W., Weinberg, S., Joseph, J., Lopez, M., Kalyanaraman, B., Mutlu, G.M., Budinger, G.R., and Chandel, N.S. (2010). Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc. Natl. Acad. Sci. USA 107, 8788–8793.

Weinberg, S.E., and Chandel, N.S. (2015). Targeting mitochondria metabolism for cancer therapy. Nat. Chem. Biol. 11, 9–15.

Wen, Z., Zhong, Z., and Darnell, J.E., Jr. (1995). Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell 82, 241–250.

Wheaton, W.W., Weinberg, S.E., Hamanaka, R.B., Soberanes, S., Sullivan, L.B., Anso, E., Glaser, A., DuFour, E., Mutlu, G.M., Budigner, G.S., et al. (2014). Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis. Elife 3, e02242.

Widlund, A.L., Baral, K., Dalgaard, L.T., and Vang, O. (2017). Functional mitochondrial STAT3 is important for the effect of resveratrol. Molecules 22, 847.

Xie, T.X., Wei, D., Liu, M., Gao, A.C., Ali-Osman, F., Sawaya, R., and Huang, S. (2004). Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene 23, 3550–3560.

Yang, R., and Rincon, M. (2016). Mitochondrial Stat3, the need for design thinking. Int. J. Biol. Sci. 12, 532–544.

Yu, C., Huo, X., Agoston, A.T., Zhang, X., Theess, A.L., Cheng, E., Zhang, Q., Zaika, A., Pham, T.H., Wang, D.H., et al. (2015). Mitochondrial STAT3 contributes to transformation of Barrett’s epithelial cells that express oncogenic Ras in a p53-independent fashion. Am. J. Physiol. Gastrointest. Liver Physiol. 309, G146–G161.

Zhang, Q., Raje, V., Yakovlev, V.A., Yacoub, A., Szczepanek, K., Meier, J., Derecka, M., Chen, Q., Hu, Y., Sisler, J., et al. (2013). Mitochondrial localized Stat3 promotes breast cancer growth via phosphorylation of serine 727. J. Biol. Chem. 288, 31280–31288.
Supplemental Information

Mitochondria-Targeted Honokiol Confers a Striking Inhibitory Effect on Lung Cancer via Inhibiting Complex I Activity

Jing Pan, Yongik Lee, Gang Cheng, Jacek Zielonka, Qi Zhang, Martina Bajzikova, Donghai Xiong, Shirng-Wern Tsaih, Micael Hardy, Michael Flister, Christopher M. Olsen, Yian Wang, Ole Vang, Jiri Neuzil, Charles R. Myers, Balaraman Kalyanaraman, and Ming You
Supplementary Materials List

Transparent Methods

Supplementary Materials and Methods

**Fig. S1.** [Synthesis of mitochondria-targeted honokiols (mito-honokiols)], Related to Fig. 1

**Fig. S2.** [NMR spectra of synthesized compounds 1, 2+3 and 4], Related to Fig. 1

**Fig. S3.** [HPLC analysis of mitochondria-targeted analogs of honokiol], Related to Fig. 1

**Fig. S4.** [Mito-HNK inhibits invasion without induction of significant cell death in lung cancer cells], Related to Fig. 3

**Fig. S5.** [Experimental setup for measurement of mitochondrial complex I and II activities in permeabilized cells], Related to Fig. 4

**Fig. S6.** [The effect of HNK and Mito-HNK (24 h treatment) on cellular ROS production], Related to Fig 4

**Fig. S7.** [Effect of Mito-HNK on the oxidation status of cytosolic (Prx1) and mitochondrial (Prx3) peroxiredoxins in three different lung cancer cell lines], Related to Fig 4

**Fig. S8.** [Role of STAT3 in the anti-proliferative and anti-invasive effects of HNK and Mito-HNK in small cell lung cancer cells], Related to Fig 6

**Fig. S9.** [Generation and validation of the STAT3 knockout H2030-BrM3 cell line], Related to Fig 6

**Fig. S10.** [Eliminating mtDNA with Herpes simplex virus UL12.5 abrogates the anti-proliferative effects of Mito-HNK in lung cancer cells], Related to Fig 5
Fig. S11. [Combination of Mito-HNK with cisplatin increased anti-proliferative effects in lung cancer cells], Related to Fig 3

Table S1. [Modified Irwin screen after 8-week Mito-HNK treatment], Related to Fig. 1

Table S2. [Gene expression in malignant tumor cells from brain metastatic lesions], Related to Fig 7

Table S3. [Gene expression in nonmalignant stromal cells from brain metastatic lesions], Related to Fig 7
Materials and Methods

Cell culture and reagents

The brain metastatic lung cancer cell lines H2030-BrM3 and PC9-BrM3 were generous gifts from Dr. Joan Massage (Memorial Sloan Kettering Cancer Center, New York, NY). H2030 and PC9 cell lines were established from lung adenocarcinoma patients; H2030 has a \( \text{KRAS}^{G12C} \) mutation (76) and PC9 has an \( \text{EGFR}^{\text{del exon19}} \) mutation (77). H2030-BrM3 and PC9-BrM3 cells are sublines that consistently form brain metastasis in 100% of animals compared to a 10% efficiency of the parental lines (39). These cells were engineered to stably express a green fluorescent protein (GFP)-luciferase fusion protein. The small cell lung cancer cell line DMS-273 was purchased from Sigma-Aldrich (St. Louis, MO). The DMS-273 cell line was established from the pleural fluid cells of an SCLC patient, who relapsed from both chemotherapy and radiotherapy, and was classified as variant SCLC, with a fast growth rate and high metastatic potential (78). The PC9-BrM3 and H2030-BrM3 cell lines were maintained in RPMI-1640 medium (11875-093, Gibco) supplemented with 10% fetal bovine serum (FBS) (Invitrogen, Carlsbad, CA). DMS-273 cells were maintained in Waymouth’s medium (11220-035, Gibco) supplemented with 10% FBS in a 37°C humidified 5% CO₂ incubator. 143B and 143B \( \rho 0 \) cells were a gift from Dr. Ole Vang, Department of Science and Environment; Roskilde University, Denmark; B16 and B16 \( \rho 0 \) cells were generously provided by Dr. Martina Bajzikova, Institute of Biotechnology, Czech Academy of Sciences, Czech Republic. Both 143B and B16 cells were cultured as previously.
described in DMEM (11965-092, Gibco) supplemented with 10% FBS, sodium pyruvate (1 mM) and uridine (50 µg/ml).

Honokiol was purchased from Sigma-Aldrich (St. Louis, MO). We synthesized mono- and bis-substituted HNK molecules as shown in Fig. 1 using a procedure described in the Supplementary Materials. The mono-substituted honokiol derivative (Mito-HNK) has been isolated as a mixture of two isomers (Supplementary Fig. 1), while only one double-substituted analog (bis-Mito-HNK) was obtained. The products were isolated on gel chromatography and purified by preparative high performance liquid chromatography (HPLC). The structure identity was confirmed by nuclear magnetic resonance (NMR) (Supplementary Fig. 2) and high resolution mass spectrometry. The purity of the compounds was rigorously tested before use by HPLC analyses (Supplementary Fig. 3).

**Cell proliferation assay**

Cells were seeded in 96-well tissue culture plates at 1,000–3,000 cells per well. Twenty-four hours after seeding, cells were exposed to various concentrations of Mito-HNK, whereas control group cells received fresh medium with an equivalent amount of dimethyl sulfoxide (DMSO) vehicle. Plates were incubated at 37°C under 5% CO₂ and monitored using the IncuCyte Live Cell analysis system (Essen Bioscience, Ann Arbor, MI). The IncuCyte™ Live-Cell Imaging Analyzer provides real-time cell confluence data, which were analyzed using the IncuCyte 2011A software. All assays were performed in triplicate or quadruplicate.
**Transwell invasion assay**

Boyden chamber transwells pre-coated with growth-factor-reduced Matrix were purchased from Fisher Scientific (Pittsburgh, PA). Transwell invasion assays were performed as described by the manufacturer’s protocol. Briefly, $2-3 \times 10^5$ cells were seeded into each transwell, filled with serum-free culture medium. The bottom wells were filled with cell culture medium or Waymouth’s medium with 10% FBS and either HNK or Mito-HNK. Controls received an equivalent amount of DMSO. After 36 hours, cells were fixed with 10% formalin and stained with 5% crystal violet in 70% ethanol. Invaded cells were counted at a magnification of 10× in three randomly selected areas of each transwell, and the results were normalized to the control.

**Toxicity studies of Mito-HNK**

All animal procedures were performed in accordance with the Medical College of Wisconsin Institutional Animal Care and Use Committee. An eight-week subchronic toxicity study was conducted in A/J mice. A Modified Irwin Screen was used employing 35 distinct measurements to assess sensorimotor, neurological, and autonomic nervous system function. A/J mice were treated with vehicle control or Mito-HNK, given via oral gavage five days per week for eight weeks. During treatment, the modified Irwin Screen was conducted at baseline (pre-treatment) and at 1, 2, 4, 6, and 8 weeks after treatment onset. Body weights were measured daily. Organ weights (liver, lungs, heart, and kidneys) were measured after eight weeks of treatment. All major organs and tissues (including brain and muscle) were subjected to pathological analysis. All tissues were fixed in a 10% zinc formalin solution overnight and stored in 70% ethanol for
histopathology evaluation. Serial tissue sections (5 μm each) were made, stained with hematoxylin and eosin (H&E), and examined histologically under a light microscope to assess any toxic effects of Mito-HNK.

**Orthotopic lung cancer mouse model**

We used an orthotopic model of lung cancer cells in non-obese/severe combined immunodeficiency (NOD/SCID) mice to evaluate the inhibitory effect of Mito-HNK on lung tumor growth. Five-week-old male NOD/SCID mice were used for these experiments. Mice were anesthetized with isoflurane and placed in the right lateral decubitus position. At eight weeks of age, H2030-BrM3 (NSCLC) or DMS-273 (SCLC) cells (1×10⁶ cells/50 μg of growth factor-reduced Matrigel [BD Biosciences, San Jose, CA] in 50 μL of Waymouth’s medium) were injected through the left rib cage of mice into the left lung, as previously described(39). One week later, mice were treated by oral gavage five days per week with HNK or Mito-HNK or vehicle (corn oil). Tumor growth was monitored by bioluminescence with the Xenogen IVIS-200 system. Mice were sacrificed at the endpoint, tissues were excised, freshly frozen, and OCT-fixed or formalin-fixed with 10% zinc for subsequent Western blot and immunohistochemistry (IHC) analyses.

**Brain metastases generated in mice via an ultrasound-guided left ventricle injection**

For the lung cancer brain metastasis study, 4–6-week-old female NOD/SCID mice were used. Brain-seeking H2030-BrM3 or DMS-273 cells (2×10⁵) were suspended in PBS (0.1 mL) and injected into the left ventricle under ultrasound guidance (ECHO 707, GE,
Milwaukee, WI). One day after engrafting lung cancer cells in the arterial circulation, mice were randomly grouped into treatment groups: vehicle control (0.1% DMSO in corn oil), HNK, or Mito-HNK. Mice were treated by oral gavage five days per week and metastases were monitored periodically by bioluminescence using a Xenogen IVIS-200 system (Alameda, CA). At sacrifice, metastases were confirmed with \textit{ex vivo} luminescence, \textit{ex vivo} GFP fluorescence, and staining with H&E and with GFP protein immunostaining.

\textit{PathScan receptor Tyrosine kinase assay}

H2030-BrM3 and DMS-273 cells were treated with vehicle control (DMSO), HNK or Mito-HNK for four hours and then lysed with a lysis buffer containing a proteinase inhibitor cocktail (Cell Signaling Technology, Danvers, MA), sheared 10 times by passage through a 28-gauge needle, and centrifuged at 16,000g for 30 min; the protein concentration of the supernatant was determined by the Bradford method. Lysates, normalized for equal protein loading, were analyzed by the PathScan RTK Signaling Array (Cell Signaling Technology, Danvers, MA) and the LI-COR Odyssey infrared imaging system (LI-COR Biosciences-Biotechnology, Lincoln, NE).

\textit{Western blot analysis}

Cells were lysed with RIPA buffer containing a proteinase inhibitor cocktail (Fisher Scientific, Pittsburg, PA), sheared 10 times by passage through a 28-gauge needle, and centrifuged at 16,000 g for 30 min; the supernatants were normalized for protein concentration as determined by the Bradford method (79). Lysates were boiled for 5 min
and resolved on 4–12% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gels (Invitrogen, Carlsbad, CA). The blots were probed with the following primary antibodies from Cell Signaling Technology (Danvers, MA): p-EGFR-Tyr1068 (#3777S), p-STAT3-Tyr705 (#9131S), p-STAT3-Ser727 (#9134S), p-AKT-Ser473 (#4060S), EGFR (#4267S), STAT3 (#9139S), AKT (#9272S), or anti-actin (sc-8432, Santa Cruz Biotechnology, Dallas, TX).

Respiratory enzyme activity
Mitochondrial function was measured using a Seahorse XF96 Extracellular Flux Analyzer (Seahorse Bioscience, North Billerica, MA), as described previously (3-5, 80). For measurement of mitochondrial respiratory complexes, after 24-h treatments as indicated, intact cells were permeabilized using 1 nM Plasma Membrane Permeabilizer (PMP, Seahorse Bioscience) immediately before OCR measurement. The oxygen consumption derived from mitochondrial complex I or II activity was measured by providing different substrates to mitochondria, e.g., pyruvate/malate for complex I and succinate for complex II. Rotenone, malonate, and antimycin A were used as specific inhibitors of mitochondrial complex I, II, and III, respectively.

Analysis of intracellular oxidants
For analysis of the effect of the treatments on intracellular oxidant production, cells were treated for 24 h with the compound of interest, followed by 1-h incubation with hydroethidine (HE, 10 µM). After incubation, cells were harvested and the cell pellet stored at −80°C until the day of HPLC analysis. Sample preparation and HPLC analysis
was performed as described previously (81, 82), with subsequent modifications (83). 2-hydroxyethidium was used as a specific marker for the superoxide radical anion, while diethidium was considered as a specific marker for one-electron oxidants(84).

Redox blots for peroxiredoxins

Redox Western blots for Prx1 and Prx3 were done as previously described (85, 86). Following treatment with Mito-HNK or vehicle control, cells were harvested to capture the protein thiol redox state: cells were washed once with Hank’s Balanced Salt Solution (Life Technologies, Carlsbad, CA) and immediately scraped into N-ethylmaleimide (NEM) extract buffer (40 mM HEPES pH 7.4, 50 mM NaCl, 100 mM NEM, 1 mM EDTA, 1 mM EGTA, 1 mM PMSF, 10 µg/mL catalase). After 15 min at room temperature, the cells were pelleted (5 min, 800 g), and then lysed on ice in 35 µL NEM extract buffer containing 1% CHAPS (3-[[3-cholamidopropyl]dimethylammonio]-1-propanesulfonate). The lysates were held at –80°C until analysis. Lysates were thawed on ice and centrifuged for 5 min (8000 g, 4°C). The supernatants were run on non-reducing SDS-PAGE (NuPAGE Novex 10% Bis-Tris gels), and the blots were probed with anti-Prx1 (sc-7381) or anti-Prx3 (sc-59661 or sc-59663) (all from Santa Cruz Biotechnology), followed by the appropriate HRP-conjugated secondary antibody. The blots were developed using SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific, Rockford, IL). Multiple exposure times were captured, and the percent of oxidized vs. reduced Prx was determined by image densitometry using UN-SCAN-IT software v.6.1 (Silk Scientific, Orem, UT).
Live cell imaging

Cells (parental or p0) growing on glass cover slides (VWR) in 6-well plates were evaluated for mtDNA depletion by live cell imaging as previously described (87). Cells were stained with PicoGreen (3 µl/ml; Invitrogen) for 1 h at 37°C to visualize mtDNA, MitoTracker Deep Red (1 µM; Invitrogen) was added and the cells were incubated for a further 20 min. After three washes with cold PBS, cells were visualized and photographed with a Zeiss SP5 confocal microscope using a 63x oil immersion objective.

Endogenous STAT3 knockdown and KO using CRISPR System

STAT3 shRNA lentiviral particles purchased from Santa Cruz Biotechnology, Inc., were used in the presence of 8 µg/mL polybrene to infect PC9-BrM3, H2030-BrM3, and DMS-273 cells. The infected cells were selected with puromycin (2 µg/mL) for three days to obtain stable knockdown cells. To generate complete knockouts of STAT3, the bicistronic pX330 vector containing cDNAs encoding human codon-optimized Streptococcus pyogenes Cas9 (hSpCas9) and an adaptable CRISPR RNA (crRNA)/trans-activating crRNA chimera containing adjacent BbsI cloning sites for protospacer “guide sequence” insertion was purchased from Addgene (plasmid no. 42230). Three guide sequences targeting DNA within the first exon of STAT3 were selected from the online design site. After annealing, the oligos were ligated into the BbsI-digested pX330 vector. After cloning and polymerase chain reaction (PCR) validation, we used the Cel-1 assay in HEK-293 cells to authenticate the cleavage of the STAT3 gene (Supplementary Fig. 8). The correct construct(s) that can successfully
cleave the target gene were then transfected into H2030-BrM3 cells, along with a puromycin transgene targeted to the AAVS1 safe harbor locus (Systems Biosciences, Palo Alto, CA) to establish puromycin-resistant clones. Each individual clone was then screened by PCR and DNA sequencing (Supplementary Fig. 8), and the knockouts were validated by Western blot. Two CRISPR-STAT3 knockout colonies had frameshift mutations, resulting in total STAT3 knockout (Supplementary Fig. 8).

Species-Specific RNAseq

Total RNA was extracted from the H2030-BrM3 brain metastatic lesions of nude mice treated with Mito-HNK or vehicle control for four weeks (n=3 per group), as described above. Total RNA (4 µg) was poly-A purified, transcribed, and chemically fragmented using Illumina’s TruSeq RNA library kit, per the manufacturer’s protocol. Individual libraries were prepared for each sample, indexed for multiplexing, and then sequenced on an Illumina HiSeq 2000 (Illumina, Inc., San Diego, CA). Sequences for all RNA transcripts were annotated using the human build GRCh37 and mouse build MGCSv37 and were then concatenated to create a joint human and mouse transcriptome reference. Reads of each xenograft sample were aligned to the joint transcriptome references using Bowtie2 (88). Default parameters were used with the exception of a Bowtie2 offset of 1, trading index size for increased alignment speed. Expression abundances were quantified at the whole transcript-level as effect counts using eXpress version 1.5.1 (89). The transcript-level count data were aggregated per gene and rounded to integer to produce gene-level count matrix. Differential expression (DE) analysis was performed with the DESeq2 (90) to compute log2 fold changes and FDR-
adjusted p-values. Statistical significance was determined at an FDR threshold of 0.05. DE analysis was carried out separately for mouse and human to allow for normalization of different relative contributions of malignant tumor cells and the nonmalignant host stroma. Species-Specific RNAseq (SSRS) data were analyzed for molecular and functional pathway enrichment using the Ingenuity IPA tool (Qiagen, Redwood City, CA).

Data and statistical analysis

To compare multiple groups, one-way analysis of variance (ANOVA) was used followed by Dunnett's post-hoc test. *P<0.05, **P<0.01, and ***P<0.001 were considered statistically significant and marked accordingly. Mice were randomly assigned to the treatment groups, and the duration that mice were followed for each experiment is shown in each figure legend section.

Synthesis of mitochondria-targeted analogs of honokiol

General. All chemicals and organic solvents were commercially available and were used as supplied. The reactions were monitored by TLC using silica gel Merck 60F254. Crude materials were purified by flash chromatography on Merck Silica gel 60 (0.040-0.063 mm). 1H NMR spectra were recorded at 400.13 MHz using a Bruker DPX AVANCE 400 spectrometer equipped with a QNP probe. 1H NMR and 31P were taken in CDCl3 using CDCl3 and TMS as internal reference, respectively. Chemical shifts (δ) are reported in ppm and J values in Hertz.

10-Bromodecyltriphenylphosphonium bromide 1. A mixture of triphenylphosphonium (1 g, 3.8 mmol) and dibromide (5.7 g, 19 mmol) was heated at 90°C for 6 h. After cooling, the crude product was purified by flash chromatography (Pentane, Et2O and CH2Cl2/EtOH 9:1) to afford the corresponding phosphonium salt 1 as a white solid (1 g, 47% yield).
Mono-mito-honokiols (\(\{10-\text{[3',5-diallyl-4'-hydroxy-(1,1'-biphenyl)-2-yl]-oxy}\)-decyldiphenylphosphonium [2] and \(\{10-\text{[3,5'-diallyl-2'-hydroxy-(1,1'-biphenyl)-4-yl]-oxy}\)-decyldiphenylphosphonium [3]\)) and bis-mito-honokiol (\([3',5\text{-diallyl-(1,1'-biphenyl)-2,4'-diyl]-bis-(oxy)-bis-(octane-10,1-diyl)-bis-(triphenylphosphonium)} [4]\)). To a mixture of honokiol (0.27 g, 2.6 mmol), anhydrous potassium carbonate (0.28, 2 mmol) in DMF (4 mL) was added to compound 1 (0.57, 1.0 mmol). The mixture was stirred at 30 °C for 6h. The solvent was removed under vacuum and the residue was taken up into water and extracted with CH\(_2\)Cl\(_2\). The organic layer was dried over Na\(_2\)SO\(_4\), and the solvent was removed under reduced pressure. Purification by flash chromatography (Et\(_2\)O, CH\(_2\)Cl\(_2\) and CH\(_2\)Cl\(_2\)/EtOH) delivered the corresponding mono-mito-honokiols as a mixture of two isomers 2, 3 and the bis-mito-honokiol 4 as white solids (2, 3, 250 mg, 33 % yield; and 4, 100 mg, 10 % yield). HRMS calculated for 2, 3 C\(_{46}\)H\(_{52}\)O\(_2\)P [MH]+ 667.3699, found, 667.3699. HRMS calculated for 4 C\(_{74}\)H\(_{86}\)O\(_2\)P\(_2\) [MH]2+ 534.3046, found, 534.3044.

**Mono-mito-honokiol 2, 3.** 31P (400.13 MHz, CDCl\(_3\)) □ 24.38, 24.28. 1H NMR (400.13 MHz, CDCl\(_3\)) □ 7.86-7.65 (15H, m), 7.35-6.95 (5H, m), 6.87 (1H, 2d, \(J = 8.3, 8.5\)), 6.06-5.86 (2H, m), 5.10-4.93 (4H, m), 3.98 (1H, t, \(J = 3.9\)), 3.89 (1H, t, \(J = 3.8\)), 3.80-3.70 (2H, m), 3.4-3.33 (4H, m), 1.77-1.30 (10H, m), 1.1-1.07 (6H, m).

**Bis-mito-honokiol 4.** 31P (400.13 MHz, CDCl\(_3\)) □ 7.88-7.70 (30H, m), 7.35-7.32 (2H, m), 7.12 (1H, d, \(J = 1.7\)), 7.07 (1H, dd, \(J = 8.3, 2.0\)), 6.88 (1H, d, \(J = 8.3\)), 6.85 (1H, d, \(J = 8.3\)), 6.05-5.85 (2H, m), 5.13-4.93 (4H, m), 3.97 (2H, t, \(J = 6.3\)), 3.90 (2H, t, \(J = 6.3\)), 3.85-3.73 (4H, m), 3.39 (2H, d, \(J = 6.8\)), 3.36 (2H, d, \(J = 6.5\)), 1.71-1.50 (10H, m), 1.20-1.33 (22H, m).

Mass spectrometry analysis of mitochondria-targeted analogs of honokiol.

HRMS calculated for 2, 3 C\(_{46}\)H\(_{52}\)O\(_2\)P [MH]+ 667.3699, found, 667.3699. HRMS calculated for 4 C\(_{74}\)H\(_{86}\)O\(_2\)P\(_2\) [MH]2+ 534.3046, found, 534.3044.
Fig. S1. Synthesis of mitochondria-targeted honokiols (mito-honokiols). Reagents and conditions: i, PPh₃, neat, 6 h, 90°C, 47%; ii, Honokiol, K₂CO₃, DMF, 43%.
Fig. S2. NMR spectra of synthesized compounds 1, 2+3 and 4. (A) $^{31}$P NMR spectrum (400.13 MHz, CDCl$_3$) of compound 1; (B) $^1$H NMR spectrum (400.13 MHz, CDCl$_3$) of compound 1; (C) and (D) same as panels (A) and (B) but for mono-mito-honokiol (compounds 2 + 3); (E) and (F) same as panels (A) and (B) but for bis-mito-honokiol (compound 4).
Fig. S3. HPLC analysis of mitochondria-targeted analogs of honokiol. (A) Analysis of *mono*-mito-honokiol. Double peak indicates of the presence of two isomers. (B) Analysis of *bis*-mito-honokiol. HPLC experiments were performed using an Agilent 1200 system equipped with UV-Vis absorption and fluorescence detectors using a C\textsubscript{18} column (Phenomenex, Kinetex C\textsubscript{18}, 100 mm × 4.6 mm, 2.6 μm) that was equilibrated with 10% CH\textsubscript{3}CN (containing 0.1% (v/v) trifluoroacetic acid (TFA) in 0.1% TFA aqueous solution. Five minutes after injection, the CH\textsubscript{3}CN fraction was increased to 40%; 10 min after injection, the CH\textsubscript{3}CN fraction was increased to 100% until 16 min. The compounds were eluted using a flow rate of 1.5 ml/min.
Fig. S4. Mito-HNK inhibits invasion without induction of significant cell death in lung cancer cells. (A) Pretreat with Mito-HNK inhibits invasion of lung cancer cells. To rule out the pro-apoptotic effects of mito-HNK, lung cancer cells H2030-BrM3 were pretreated with different doses of mito-HNK for 24 hours, then mito-HNK was washed out, cells were trypsinized and plated in the Boyden chamber for invasion assay. Representative images are shown in left panel and the quantitative data are in the right panel. (B) Mito-HNK does not cause cells death at low doses. Lung cancer cells were treated with different doses of mito-HNK for 24 or 48 hr, supernatant was collected and subjected for LDH cytotoxicity assay following manufacturer’s instruction. (C) Mito-HNK blocks cell cycle.
Fig. S5

Fig. S5. Experimental setup for measurement of mitochondrial complex I and II activities in permeabilized cells. H2030-BrM3 (A) or DMS-273 (B) cells were permeabilized and assayed in medium containing 10 mM pyruvate and 1.5 mM malate (substrates for complex I) in mannitol and sucrose (MAS) buffer using the Seahorse XF96 analyzer. Either rotenone (1 µM, complex I inhibitor) or malonate (10 mM, complex II inhibitor) was added immediately before starting the measurements of oxygen consumption rate (OCR). Both succinate (10 mM, substrate for complex II) and antimycin A (20 µM, complex III inhibitor) were injected as indicated.
**Fig. S6.** The effect of HNK and Mito-HNK (24 h treatment) on cellular ROS production, as measured by HPLC-based profiling of the oxidation products of the HE probe in H2030-BrM3 cells. 2-hydroxyethidium (2-OH-\(\cdot\)) is used as a specific product for superoxide, and diethidium (\(\cdot\)-\(\cdot\)) as a marker product for one-electron oxidants. **\(p < 0.01\), ***\(p < 0.001\).
Fig. S7. Effect of Mito-HNK on the oxidation status of cytosolic (Prx1) and mitochondrial (Prx3) peroxiredoxins in three different lung cancer cell lines. Cells were treated with the indicated concentrations of Mito-HNK for 24 h and the redox status of peroxiredoxins determined, as described in the experimental section.
Fig. S8. Role of STAT3 in the anti-proliferative and anti-invasive effects of HNK and Mito-HNK in small cell lung cancer cells.  

A. Results of receptor tyrosine kinase proteomic array of DMS-273 SCLC cells treated with HNK (20 µM) or Mito-HNK (0.2 µM) for 24 h.

B. Western blot analysis showing the effect of HNK and Mito-HNK on STAT3 phosphorylation status in DMS-273 and H446 SCLC cells.
Fig. S9. Generation and validation of STAT3 knockout H2030-BrM3 cell line. (A) Cel-1 assay, a mismatch-specific endonuclease assay. Genomic PCR (gPCR) products spanning exon 1 of STAT3 gene were amplified from the template of a heterogeneous population of HEK293T cells transfected with px330-STAT3 guide. Rehybridization and treatment with Cel1 nuclease resulted in fallout bands of ∼150–250 bp, shown by arrows. This is consistent with the predicted cleavage sizes of 251 bp and 176 bp. (B) After clone isolation, PCR amplicons of clonal STAT3 KO isolates (clone 17 and clone 28) encompassing the modified locus of genomic DNA were sequenced which shows that clone #17 contains a 1-bp insertion, and #28 contains a 46-bp deletion in both alleles.
Fig. S10. Eliminate mtDNA with Herpes simplex virus UL12.5 abrogates anti-proliferative effects of Mito-HNK in lung cancer cells. (A,B) Loss of mitochondrial function was seen in UL12.5 transfected H2030-BrM3 cells as evidenced by very low levels for complex I-dependent OCR and intact cell OCR. (C) UL12.5 transfected H2030-BrM3 cells are more resistant to Mito-HNK treatment, indicating that mitochondria are an important target for Mito-HNK.
Fig. S11. Combination of Mito-HNK with cisplatin increased anti-proliferative effects in lung cancer cells. H2030-BrM3 cells were treated with mito-HNK alone or in combination with cisplatin, confluency was monitored using Incucyte every three hours,
Table. S1. Modified Irwin screen after 8-week Mito-HNK treatment. Values reflect the mean ± SEM of the deviation score (0=normal, 1=mild deviation, 2=moderate deviation, 3=extreme deviation) or metric noted for each attribute after 8-week treatment with Mito-HNK or vehicle. Observations were conducted by two different experimenters and the scores were averaged.

| Physical condition          | vehicle | 2x   | 10x  | 20x  |
|-----------------------------|---------|------|------|------|
| Body weight (g)             | 22.0±0.8| 21.8±0.4| 20.8±1.3| 20.8±1.0|
| Rectal temperature (°C)     | 35.2±0.8| 34.0±0.5| 34.2±0.3| 34.0±0.4|
| Presence of whiskers        | 0.0±0.0 | 0.0±0.0 | 0.0±0.0 | 0.0±0.0 |
| Well-groomed                | 0.0±0.0 | 0.0±0.0 | 0.0±0.0 | 0.0±0.0 |
| Pilonecrosis                 | 0.6±0.2 | 0.4±0.2 | 0.8±0.3 | 0.0±0.0 |
| Fur missing on face         | 0.0±0.0 | 0.0±0.0 | 0.0±0.0 | 0.0±0.0 |
| Fur missing on body         | 0.0±0.0 | 0.0±0.0 | 0.0±0.0 | 0.0±0.0 |
| Wounds                      | 0.0±0.0 | 0.0±0.0 | 0.0±0.0 | 0.0±0.0 |
| Skin color                  | 0.0±0.0 | 0.0±0.0 | 0.0±0.0 | 0.0±0.0 |
| Palpebral closure           | 0.2±0.2 | 0.0±0.0 | 0.0±0.0 | 0.0±0.0 |

| Behavior in novel environment |
|-------------------------------|
| Transfer behavior             | 1.4±0.2 | 1.8±0.7 | 1.3±0.3 | 1.2±0.2 |
| Body positioning              | 0.0±0.0 | 0.0±0.0 | 0.3±0.3 | 0.0±0.0 |
| Spontaneous activity          | 0.0±0.0 | 0.0±0.0 | 0.0±0.0 | 0.0±0.0 |
| Respiration rate              | 0.8±0.2 | 0.6±0.2 | 0.5±0.3 | 0.2±0.2 |
| Tremor                        | 0.0±0.0 | 0.0±0.0 | 0.0±0.0 | 0.0±0.0 |
| Pilonecrosis                  | 1.0±0.0 | 0.6±0.2 | 0.8±0.3 | 0.4±0.2 |
| Gait                          | 0.0±0.0 | 0.0±0.0 | 0.0±0.0 | 0.0±0.0 |
| Pelvic elevation              | 0.2±0.2 | 0.4±0.2 | 0.0±0.0 | 0.2±0.2 |
| Tail elevation                | 0.0±0.0 | 0.0±0.0 | 0.0±0.0 | 0.0±0.0 |
| Uritination                   | 0.0±0.0 | 0.0±0.0 | 0.0±0.0 | 0.0±0.0 |
| Defecation                    | 0.4±0.2 | 0.4±0.2 | 0.0±0.0 | 0.0±0.0 |

| Reflexes or reaction to stimuli |
|---------------------------------|
| Touch escape                    | 0.8±0.2 | 1.0±0.0 | 1.0±0.0 | 0.8±0.2 |
| Positional passivity            | 1.2±0.2 | 1.0±0.0 | 1.5±0.3 | 1.0±0.0 |
| Trunk curl                      | 0.0±0.0 | 0.0±0.0 | 0.0±0.0 | 0.0±0.0 |
| Reaching reflex                 | 0.0±0.0 | 0.0±0.0 | 0.0±0.0 | 0.0±0.0 |
| Pinna reflex                    | 0.0±0.0 | 0.0±0.0 | 0.0±0.0 | 0.0±0.0 |
| Preyer reflex at -90 dB         | 0.6±0.2 | 0.8±0.2 | 0.8±0.3 | 0.0±0.0 |
| Toe pinch response              | 0.0±0.0 | 0.0±0.0 | 0.0±0.0 | 0.0±0.0 |
| Righting reflex                 | 0.0±0.0 | 0.0±0.0 | 0.0±0.0 | 0.0±0.0 |
| Air righting reflex             | 0.0±0.0 | 0.0±0.0 | 0.0±0.0 | 0.0±0.0 |
| Inverted screen latency to fall (s)| 49.2±10.1 | 50.8±5.6 | 49.0±11.0 | 60.0±10.0 |
| Provoked biting                 | 1.0±0.0 | 1.0±0.0 | 1.0±0.0 | 1.0±0.0 |

| Measures during supine restraint |
|---------------------------------|
| Limb tone                       | 0.2±0.2 | 0.2±0.0 | 0.2±0.3 | 0.0±0.0 |
| Abdominal tone                  | 0.8±0.2 | 0.6±0.2 | 0.3±0.3 | 0.4±0.2 |
| Toe pinch                       | 0.0±0.0 | 0.0±0.0 | 0.0±0.0 | 0.0±0.0 |

Values reflect the mean ± SEM of the deviation score (0=normal, 1=mild deviation, 2=moderate deviation, 3=extreme deviation) or metric noted for each attribute after 8-week treatment with Mito-HNK or vehicle. Observations were conducted by two different experimenters and the scores were averaged.
Table. S2. Gene expression in malignant tumor cells from brain metastatic lesions of mice treated with Mito-HNK or vehicle control (Attached Excel file: Table. S2.xlsx)

Table. S3. Gene expression in nonmalignant stromal cells from brain metastatic lesions of mice treated with Mito-HNK or vehicle control (Attached Excel file: Table. S3.xlsx)